
X
Boosting clinical trial productivity to prove Eroom wrong
https://pharmaphorum.com/r-d/boosting-clinical-trial-productivity-to-prove-eroom-wrong/
Backed by a $202 million fundraiser, biotech Aimmune has announced plans to file its potential peanut allergy treatment at the end of the year following a phase 3 trial success.
Owlstone Medical, the innovative company which promises to revolutionise the diagnosis of cancer by simply analysing a patient’s breath has been given a major funding boost.
DNAnexus focuses on cloud-based R&D